Versant Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Versant Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.1K	Hold	80	–	–	﹤0.01%	2556
2026 Q1	$1.89K	Hold	80	–	–	﹤0.01%	2578
2025 Q4	$2.32K	Sell	80 -135	-63%	-$3.46K	﹤0.01%	2427
2025 Q3	$4.05K	Hold	215	–	–	﹤0.01%	2289
2025 Q2	$3.01K	Hold	215	–	–	﹤0.01%	2300
2025 Q1	$3.36K	Hold	215	–	–	﹤0.01%	2173
2024 Q4	$3K	Hold	215	–	–	﹤0.01%	1957
2024 Q3	$2K	Buy	+215	New	+$2.12K	﹤0.01%	1564

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Versant Capital Management's ARQT Position: Q2 2026 in Review

Versant Capital Management held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 80 shares worth $2.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2556.

Versant Capital Management first reported a position in ARQT in Q3 2024 and has held it in 8 quarters since. The position peaked at $4.05K in Q3 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Versant Capital Management held 80 shares of Arcutis Biotherapeutics worth $2.1K as of Q2 2026.
Versant Capital Management left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
Arcutis Biotherapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2556 holding.
Versant Capital Management first reported a position in Arcutis Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
Versant Capital Management's Arcutis Biotherapeutics position peaked at $4.05K in Q3 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.